{"id":"https://openalex.org/W4401200857","doi":"https://doi.org/10.1093/cvr/cvae166","title":"ORION-8: one step closer to understanding the safety and efficacy of inclisiran","display_name":"ORION-8: one step closer to understanding the safety and efficacy of inclisiran","alternate_titles":[],"publication_year":2024,"publication_date":"2024-07-31","ids":{"openalex":"https://openalex.org/W4401200857","doi":"https://doi.org/10.1093/cvr/cvae166","pmid":"https://pubmed.ncbi.nlm.nih.gov/39082271"},"language":"en","primary_location":{"id":"doi:10.1093/cvr/cvae166","doi":"https://doi.org/10.1093/cvr/cvae166","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cvr/cvae166","pdf_url":"https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvae166/58917346/cvae166.pdf","source":{"id":"https://openalex.org/S91067379","display_name":"Cardiovascular Research","issn_l":"0008-6363","issn":["0008-6363","1755-3245"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4401200857"],"child_works_count":0,"type":"editorial","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvae166/58917346/cvae166.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023972061","display_name":"Lale S Tokg\u00f6zo\u011flu","orcid":"https://orcid.org/0000-0001-6441-3339","observed_orcids":["https://orcid.org/0000-0001-6441-3339"]},"institutions":[{"id":"https://openalex.org/I66514158","display_name":"Hacettepe University","ror":"https://ror.org/04kwvgz42","country_code":"TR","type":"education","lineage":["https://openalex.org/I66514158"]}],"countries":["TR"],"is_corresponding":false,"raw_author_name":"Lale Tokg\u00f6zo\u011flu","raw_affiliation_strings":["Department of Cardiology, Hacettepe University School of Medicine, Ankara, Turkey"],"raw_orcid":"https://orcid.org/0000-0001-6441-3339","affiliations":[{"raw_affiliation_string":"Department of Cardiology, Hacettepe University School of Medicine, Ankara, Turkey","institution_ids":["https://openalex.org/I66514158"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000214404","display_name":"Giuseppe Danilo Norata","orcid":"https://orcid.org/0000-0002-6081-1257","observed_orcids":["https://orcid.org/0000-0002-6081-1257"]},"institutions":[{"id":"https://openalex.org/I189158943","display_name":"University of Milan","ror":"https://ror.org/00wjc7c48","country_code":"IT","type":"education","lineage":["https://openalex.org/I189158943"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Giuseppe Danilo Norata","raw_affiliation_strings":["Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133, Milan, Italy"],"raw_orcid":"https://orcid.org/0000-0002-6081-1257","affiliations":[{"raw_affiliation_string":"Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133, Milan, Italy","institution_ids":["https://openalex.org/I189158943"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5000214404"],"corresponding_institution_ids":["https://openalex.org/I189158943"],"apc_list":{"value":4951,"currency":"EUR","value_usd":5358},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"120","issue":"12","first_page":"1365","last_page":"1366"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.8159999847412109},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.7689999938011169},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.6959999799728394},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.8429999947547913},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.777999997138977},{"id":"https://openalex.org/keywords/pcsk9-monoclonal-antibodies","display_name":"PCSK9 monoclonal antibodies","score":0.8019999861717224},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.6119999885559082},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.6800000071525574},{"id":"https://openalex.org/keywords/cardiovascular-risk-reduction","display_name":"cardiovascular risk reduction","score":0.43799999356269836},{"id":"https://openalex.org/keywords/pooled-analysis-of-clinical-trials","display_name":"pooled analysis of clinical trials","score":0.5799999833106995},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.3330000042915344},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.6039999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4133642911911011}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D034741","descriptor_name":"RNA, Small Interfering","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1093/cvr/cvae166","doi":"https://doi.org/10.1093/cvr/cvae166","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cvr/cvae166","pdf_url":"https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvae166/58917346/cvae166.pdf","source":{"id":"https://openalex.org/S91067379","display_name":"Cardiovascular Research","issn_l":"0008-6363","issn":["0008-6363","1755-3245"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Research","raw_type":"journal-article"},{"id":"pmid:39082271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39082271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular research","raw_type":"Editorial"},{"id":"pmh:oai:air.unimi.it:2434/1117512","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/2434/1117512","pdf_url":null,"source":{"id":"https://openalex.org/S4306400516","display_name":"Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I189158943","host_organization_name":"University of Milan","host_organization_lineage":["https://openalex.org/I189158943"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1093/cvr/cvae166","doi":"https://doi.org/10.1093/cvr/cvae166","is_oa":true,"landing_page_url":"https://doi.org/10.1093/cvr/cvae166","pdf_url":"https://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvae166/58917346/cvae166.pdf","source":{"id":"https://openalex.org/S91067379","display_name":"Cardiovascular Research","issn_l":"0008-6363","issn":["0008-6363","1755-3245"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cardiovascular Research","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4401200857.pdf","grobid_xml":"https://content.openalex.org/works/W4401200857.grobid-xml"},"referenced_works_count":9,"referenced_works":["https://openalex.org/W2900034165","https://openalex.org/W2911014938","https://openalex.org/W3179582567","https://openalex.org/W3183857127","https://openalex.org/W4293426420","https://openalex.org/W4383711438","https://openalex.org/W4389303227","https://openalex.org/W4397024469","https://openalex.org/W6756602680"],"related_works":["https://openalex.org/W4376128572","https://openalex.org/W4390399540","https://openalex.org/W4287377970","https://openalex.org/W4283747817","https://openalex.org/W4402904392","https://openalex.org/W4385407137","https://openalex.org/W7165192369","https://openalex.org/W3096580040","https://openalex.org/W4313554841","https://openalex.org/W4393314184"],"abstract_inverted_index":{"This":[0,348,387],"editorial":[1],"refers":[2],"to":[3,221,249,328,379,394,396,675,694,728,732,748,833],"\u2018Inclisiran":[4],"administration":[5,334],"potently":[6],"and":[7,95,125,130,139,155,204,214,238,263,306,344,365,499,510,538,551,576,635,752,796,819],"durably":[8],"lowers":[9],"LDL-C":[10,105,123,343,430,492,521,559,568,607,630,639,647,775,836],"over":[11,661,740],"an":[12,629,638,705,766],"extended-term":[13],"follow-up:":[14],"the":[15,28,53,83,143,152,171,194,210,224,236,260,320,330,377,382,390,412,422,435,438,450,456,490,518,525,542,556,562,588,605,620,678,697,702,734,756,784,799,809,812,816,826],"ORION-8":[16,324,703,813],"trial\u2019,":[17],"by":[18,167],"R.":[19],"Scott":[20],"Wright":[21],"et":[22],"al.,":[23],"https://doi.org/10.1093/cvr/cvae109.":[24],"The":[25,186,218,323,404,469,823],"discovery":[26],"of":[27,30,41,55,60,86,137,145,173,183,196,227,230,241,273,332,335,342,360,371,401,407,414,437,441,471,532,544,595,602,619,626,646,658,664,687,720,768,788,811,821,825],"role":[29,144],"proprotein":[31],"convertase":[32],"subtilisin/kexin":[33],"type":[34],"9":[35],"(PCSK9)":[36],"as":[37,151,476,485],"a":[38,49,75,93,101,368,399,418,426,592,599,654,662,682,717],"key":[39,405],"regulator":[40],"low-density":[42],"lipoprotein":[43],"cholesterol":[44],"(LDL-C)":[45],"levels":[46,106,124,166,341,431,648],"has":[47,114,389],"represented":[48],"fundamental":[50],"opportunity":[51],"for":[52,496,502,529,801],"treatment":[54,242,281,301,622],"patients":[56,255,296,338,352,443,454,464,472,498,503,533,545,575,580,627,671,692,760,789],"at":[57,297,319,434,613],"high":[58,345,478,486],"risk":[59,467,482,506,583],"atherosclerotic":[61],"cardiovascular":[62,174,199,298,346,659,689,839],"disease":[63],"(ASVCD).":[64],"Since":[65],"then,":[66],"several":[67,96],"approaches":[68],"targeting":[69],"PCSK9":[70,146,165],"have":[71,99],"been":[72,115],"developed,1":[73],"including":[74],"small":[76],"interfering":[77],"RNA":[78],"(inclisiran)":[79],"that":[80,188,280,411,709,786],"specifically":[81],"inhibits":[82],"hepatic":[84],"synthesis":[85],"this":[87,408,743,750,791],"protein.":[88],"Inclisiran":[89,129,162],"is":[90,158,201,205,284,385,726],"administered":[91,288,416],"twice":[92,417],"year,":[94],"clinical":[97,109,277,358,757,769,805],"trials":[98,176,278,359,384,754,828],"shown":[100],"\u223c50%":[102],"reduction":[103,428,458],"in":[104,121,134,147,209,254,259,266,289,295,337,381,429,449,463,524,561,573,579,587,677,685,759,790,804],"under":[107],"various":[108],"conditions.":[110],"Therapy":[111],"with":[112,190,243,282,291,302,310,339,367,398,461,465,473,504,581,591,624,649,653,712,716,736,762,829],"inclisiran":[113,191,228,283,303,336,361,380,395,415,448,713,737,763,830],"approved":[116],"based":[117,516],"on":[118,223,445,517],"its":[119,126],"efficacy":[120,240,413,820],"reducing":[122],"safety":[127,237,313,723,818],"profile.":[128],"monoclonal":[131,184],"antibodies":[132],"differ":[133],"their":[135],"mechanisms":[136],"action":[138],"pharmacokinetic":[140],"profiles.":[141],"Furthermore,":[142],"extrahepatic":[148],"tissues":[149],"such":[150],"brain,":[153],"kidney,":[154],"immune":[156],"system":[157],"not":[159,308,746],"well":[160,285],"understood.2,3":[161],"reduces":[163,193],"plasma":[164],"about":[168],"80%;":[169],"therefore,":[170],"results":[172,810,824],"outcome":[175,827],"may":[177],"be":[178,778],"somewhat":[179],"different":[180],"from":[181,275,772,780],"those":[182],"antibodies.":[185],"demonstration":[187],"therapy":[189,711],"also":[192],"incidence":[195,719],"major":[197,688],"adverse":[198,317],"events":[200,314,660,690],"still":[202],"awaited":[203,832],"currently":[206],"being":[207],"investigated":[208],"ORION-4,":[211],"VICTORION-1":[212],"Prevent,":[213],"VICTORION-2":[215],"Prevent":[216],"trials.":[217,452,806],"studies":[219,246,262],"published":[220],"date":[222],"lipid-lowering":[225,293],"effect":[226,331],"are":[229,764,831],"short":[231],"duration.":[232],"To":[233],"determine":[234],"both":[235],"long-term":[239,333,817],"inclisiran,":[244],"two":[245,252],"were":[247,444,673,793],"designed":[248,747],"investigate":[250,329],"these":[251,530,547,781],"aspects":[253],"who":[256,353,488,672],"had":[257,354,681],"participated":[258,265],"original":[261,621],"subsequently":[264],"open-label":[267,698],"extension":[268,699],"studies.":[269],"A":[270],"pooled":[271],"analysis":[272,707],"data":[274],"seven":[276],"showed":[279,708],"tolerated":[286],"when":[287,514],"combination":[290],"other":[292,315],"therapies":[294],"risk.4":[299],"Prolonged":[300],"was":[304,307,326,410,432,508,549,565,570,609,615,651,714,738,745],"safe":[305],"associated":[309,652,715],"any":[311],"specific":[312,753],"than":[316,666,691],"reactions":[318],"injection":[321],"site.4":[322],"trial":[325,349,388,680,792],"run":[327],"elevated":[340],"risk.5":[347],"included":[350,523],"3274":[351],"completed":[355],"four":[356],"previous":[357],"(ORION-3,":[362],"ORION-9,":[363],"ORION-10,":[364],"ORION-11),":[366],"mean":[369,557],"follow-up":[370,594],"2.6":[372],"years":[373,375,597],"(3.7":[374],"if":[376],"exposure":[378,393,601],"parent":[383,451],"included).":[386],"longest":[391],"cumulative":[392],"date,":[397],"maximum":[400,600],"6.8":[402],"years.5":[403],"finding":[406],"study":[409,744,814],"year":[419],"persisted":[420],"throughout":[421],"observation":[423],"period.":[424],"Overall,":[425],"49.4%":[427],"observed":[433],"end":[436],"study,":[439,704],"regardless":[440,618],"whether":[442],"placebo":[446,695],"or":[447,480],"ASCVD":[453,466,474,481,497,505,574,582],"achieved":[455,489],"largest":[457],"(\u221251%":[459],"compared":[460],"\u221242.4%":[462],"equivalent).5":[468],"proportion":[470,543],"(categorized":[475,484],"very":[477],"risk)":[479,487],"equivalent":[483],"pre-specified":[491],"goals":[493,522,548],"(<70":[494],"mg/dL":[495,501,537,572,578,611,634],"<100":[500],"equivalent)":[507],"79.4%":[509],"74.3%,":[511],"respectively.6":[512],"However,":[513],"analysed":[515],"more":[519,665],"stringent":[520],"current":[526],"ESC/EAS":[527],"guidelines":[528],"categories":[531],"(LDL-C":[534,612],"<":[535,632,641],"55":[536,642],"<70":[539],"mg/dL,":[540],"respectively),7":[541],"achieving":[546,628,637],"66.3%":[550],"46.6%,":[552],"respectively.":[553],"Of":[554],"note,":[555],"baseline":[558,614],"level":[560,608,631,640],"overall":[563],"population":[564],"112":[566],"mg/dL;":[567],"value":[569],"104":[571],"147":[577],"equivalent.5":[584],"By":[585],"comparison,":[586],"FOURIER-OLE":[589],"trial,":[590],"median":[593,606],"5.0":[596],"(and":[598],"8.4":[603],"years),":[604],"30":[610],"\u223c90":[616],"mg/dL),":[617],"assignment,":[623],"87.3%":[625],"70":[633],"80.3%":[636],"mg/dL.8":[643],"Long-term":[644],"lowering":[645,776,837],"evolocumab":[650,676],"persistently":[655],"lower":[656,718],"rate":[657],"period":[663],"8":[667],"years.8":[668],"As":[669],"expected,":[670],"randomized":[674,693],"FOURIER":[679],"greater":[683,802],"benefit":[684,735,770],"terms":[686],"during":[696],"trial.8":[700],"In":[701,807],"exploratory":[706],"earlier":[710,773],"treatment-emergent":[721],"MACE-related":[722],"events.5":[724],"It":[725],"encouraging":[727],"see":[729],"that,":[730],"similar":[731],"FOURIER-OLE,":[733],"accrued":[739],"time.":[741],"Although":[742],"answer":[749],"question,":[751],"evaluating":[755],"outcomes":[758],"treated":[761],"ongoing,":[765],"indication":[767],"deriving":[771],"significant":[774],"can":[777],"drawn":[779],"observations.":[782],"Nevertheless,":[783],"fact":[785],"majority":[787],"white,":[794],"male,":[795],"obese":[797],"highlights":[798],"need":[800],"diversity":[803],"summary,":[808],"confirm":[815],"inclisiran.":[822],"translate":[834],"sustained":[835],"into":[838],"protection.":[840]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4401200857","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2024-08-01T00:00:00"}
